[Kidney transplantation in a patient with haemophilia A].

Transfus Clin Biol

Laboratoire d'hématologie, CHU Ibn Rochd, 1, rue des Hôpitaux, Casablanca, Maroc.

Published: February 2010

A 37-year-old patient with moderate haemophilia A and end-stage renal disease underwent kidney transplantation in the University Hospital Ibn Rochd of Casablanca (Morocco). He received factor VIII replacement therapy perioperatively and until the 21st day postoperation. So, the activity rates of Factor VIII was higher than or equal to 80 % in the day of intervention and two to three days later, then between 30 and 60 % until healing. The evolution of the patient to 28 months post-transplantation is marked by a good renal function without episode of rejection or bleeding complications. The heavy surgical interventions are possible in patients with haemophilia, but depend on good replacement therapy in peri- and postoperation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tracli.2009.09.003DOI Listing

Publication Analysis

Top Keywords

factor viii
8
replacement therapy
8
[kidney transplantation
4
transplantation patient
4
patient haemophilia
4
haemophilia 37-year-old
4
37-year-old patient
4
patient moderate
4
moderate haemophilia
4
haemophilia end-stage
4

Similar Publications

Retinal vein occlusion (RVO) is the leading cause of vision loss due to an obstruction in the retinal venous system. While RVO is often linked to thrombotic tendencies and coagulation abnormalities, the exact role of coagulation traits in its development is not fully understood. This study aims to investigate the potential causal relationship between coagulation traits and the risk of RVO by analyzing publicly available genome-wide association study (GWAS) summary statistics.

View Article and Find Full Text PDF

Abnormal base excision repair (BER) pathway and N6-methyladenosine (m6A) of RNA have been proved to be significantly related to age-related cataract (ARC) pathogenesis. However, the relationship between the Nei Endonuclease VIII-Like1 (NEIL1) gene (a representative DNA glycosylase of BER pathway) and its m6A modification remains unclear. Here, we showed that the expression of NEIL1 was decreased in the ARC anterior lens capsules and HO-stimulated SRA01/04 cells.

View Article and Find Full Text PDF

Desmopressin (DDAVP) can be used to prevent or stop bleeding. However, large inter-individual variability is observed in DDAVP response and determinants are largely unknown. In this systematic review and meta-analysis we aim to identify the response to DDAVP, and the factors that determine DDAVP response in patients.

View Article and Find Full Text PDF

Objective: Emicizumab promotes efficacious hemostasis in persons with hemophilia A persons with hemophilia A with and without inhibitors. Primary analyses of real-world data and clinical trials have shown emicizumab efficacy and safety; however, long-term data are limited.

Methods: This retrospective study was conducted to assess real-world long-term outcomes of pediatric patients on emicizumab in our hemophilia center between the period of February 2018 and September 2023.

View Article and Find Full Text PDF

Hemophilia A (HA) is associated with FVIII coagulation insufficiency or inactivity leading to excessive bleeding. Elevated FVIII, on the contrary, is associated with thrombophilia, thrombosis, myocardial infarctions, and stroke. Active FVIII (aFVIII) uses its C2 domain to bind to blood cells' membranes, consequently carrying out its coagulative function.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!